Outset Medical, Inc. (NASDAQ:OM) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET

Company Participants

Jim Mazzola - Vice President Investor Relations

Leslie Trigg - Chair & Chief Executive Officer

Nabeel Ahmed - Chief Financial Officers

Conference Call Participants

Travis Steed - Bank of America

Josh Jennings - Cowen

Suraj Kalia - Oppenheimer

Rick Wise - Stifel

Phil Coover - Goldman Sachs

Drew Ranieri - Morgan Stanley

Josh Jennings - Cowen

Operator

Greetings, and welcome to Outset Medical Q2 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn this conference over to your host Mr. Jim Mazzola, Vice President Investor Relations. Thank you, sir. You may begin.

Jim Mazzola

Okay. Thank you, and good afternoon, everyone. I'm here with Leslie Trigg, Chair and Chief Executive Officer; and Nabeel Ahmed, Chief Financial Officer.

During today's call, we will provide an update on the listing of our Tablo ship hold discuss our second quarter operational and financial results, and provide an update on our outlook for 2022. After our prepared remarks, we will host a question-and-answer session. We issued a news release earlier today and updated our investor presentation, both of which can be found on the investor pages of outsetmedical.com.

This call is being recorded, and will be archived in the Investors section of our website. It is our intent that, all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Statements that relate to expectations or predictions of future events, market trends, results, or performance are forward-looking statements.

All forward-looking statements are based on our current estimates and various assumptions, and involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied. Outset assumes no obligation to update these statements.

For a list and description of the risks and uncertainties associated, with our business, please refer to the Risk Factors section of Outset's public filings, with the Securities and Exchange Commission, including our latest annual and quarterly reports.

With that, let me turn the call over to Leslie.

Leslie Trigg

Thanks, Jim. Good afternoon, everyone, and thank you for joining us. Today, we are pleased to announce that FDA completed its review and cleared our previously disclosed 510(k) submission on updates made to Tablo. With this clearance, we have lifted our home ship hold and will resume supporting new patients in the home.